Wegovy and Zepbound get primetime treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a look at a pioneering new gene therapy, the plight of WuXi AppTec, and a rough month for biotech’s neuroscience renaissance.
Read Original Article: Wegovy and Zepbound get primetime treatment »
